Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study
- 687 Downloads
The objective of the present study was to evaluate the effect of the switch of aromatase inhibitors (AIs) on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer. This was a 6-month, prospective, non-randomized, multicenter study. Patients who had discontinued anastrozole due to musculoskeletal symptoms were eligible to participate in this study, and received letrozole, which was initiated 1 month after anastrozole discontinuation. Musculoskeletal symptoms were systematically assessed for severity, location of the symptoms, presence of swelling and of morning stiffness by the oncologist patients when patients stopped taking their anastrozole, 1 month after the discontinuation of anastrozole, and 1, 3, and 6 months after initiating the letrozole therapy. The primary endpoint was the percentage of patients who discontinued letrozole due to the severe musculoskeletal symptoms. After switching from anastrozole therapy, and at the end of the 6-month letrozole treatment, 128 (71.5%) out of 179 patients (61.3 ± 8.4 years) continued with letrozole. Fifty-one patients (28.5%) discontinued treatment due to severe joint pain. At the end of the 6-month, 116 patients (73.9%) had arthralgia, 33 (21.0%) myalgia, 25 (15.9%) arthritis, 22 (14.0%) tendinitis, and 20 (12.7%) polyalgic syndrome. Bivariate analysis of the factors associated with letrozole discontinuation showed that the duration of a prior anastrozole treatment was a significant predictor (P = 0.04). This study shows that in patients intolerant to one AI, switching to another agent allows a higher proportion of patients to continue the therapy and maximize hormonal adjuvant therapy and disease outcome benefits.
KeywordsAromatase inhibitors Letrozole Musculoskeletal symptoms Postmenopausal breast cancer
We thanks the investigators Drs the Dr Boniface-Gelas, Spaeth, Panis, Lucas, Yazbek, Bressac, Hardy-Bessard, Provencal, Fignon, Coeffic, De St Hilaire, Resbeut, Abadie, Krzich, Douadi-Gaci, Audrin, Abboud, Rotarski, Mercier Blas, Beatrix, Karst-Provost, Denis, Facchini, Azria, Mention, Campone, Laplaige, Cals, Delozier, Ellis, Mouysset, Pivot, Lecuru, Malaurie-Agostini, Meunier.
Conflict of interest statement
K Briot and C Roux received honoraria of Novartis. M Tubiana-Hulin has no conflict of interest to disclosure. L Bastit has no conflict of interest to disclosure. Ioana Kloos is medical oncologist, and an employee of Novartis
- 1.Winer EP, Hudis C, Burstein HJ et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor positive breast cancer: status report 2004. J Clin Oncol 23:619–629CrossRefPubMedGoogle Scholar
- 15.Renshaw L, McHugh M, Williams L et al (2007) Comparison of joint problems as reported by patients in a randomized adjuvant trial of anastrozole and letrozole. Breast Cancer Res Treat 106:S108Google Scholar
- 16.Cleeland CS (1989) Measurement of pain by subjective report. In: Chapman CR, Loeser JD (eds) Issues in pain measurement. Advances in pain research and therapy, vol 12. Raven Press, New York, pp 391–403Google Scholar
- 20.Thomas R, Godward S, Makris A, Bloomfield D, Moody AM, Williams M (2004) Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole. Clin Oncol (R Coll Radiol) 16:485–491Google Scholar
- 24.Zumoff B (1982) Relationship of obesity to blood estrogens. Cancer Res 42(8 Suppl):289–294Google Scholar